Capricor Therapeutics traded at $25.51 this Wednesday March 4th, decreasing $0.33 or 1.28 percent since the previous trading session. Looking back, over the last four weeks, Capricor Therapeutics lost 10.77 percent. Over the last 12 months, its price rose by 101.66 percent. Looking ahead, we forecast Capricor Therapeutics to be priced at 27.08 by the end of this quarter and at 24.67 in one year, according to Trading Economics global macro models projections and analysts expectations.
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. It consists of cell therapy program, including CAP-1002 with Duchenne muscular dystrophy program and CAP-1002 with COVID-19 (SARS-CoV-2) program. It also includes exosomes program, such as exosome-based vaccines, exosome-based therapeutics and CDC-Derived Exosomes (CAP-2003). Duchenne muscular dystrophy program has completed HOPE-2, a Phase II clinical trial in the United States with its product candidate.CAP-1002 is a cardiac cell derived therapy used to treat patients with late-stage Duchenne muscular dystrophy. The Company has received the United States Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for a clinical study of CAP-1002 in patients with severe or critical COVID-19.